TELEROUTE
The activity registered on the Teleroute Freight Exchange has been experiencing an upward trend for several weeks following the strong increase in demand for their solution during the Coronavirus crisis, demonstrating the resilience and anti-cyclical nature of one of Europe’s leading freight exchanges.
After the initial shock to the European market due to the Coronavirus, the Teleroute Freight Exchange, that together with 123Cargo and Wtransnet form one of the largest European transport collaboration networks, confirms the return of activity with a notable upturn in the number of freight offers in recent weeks , placing the activity at pre-coronavirus level and even higher in the last weeks of July, exhibiting none of the typical seasonal slowdown.
The most difficult moment for the transportation industry due to the crisis took place in April, where the complete stoppage of industrial activity throughout Europe caused freight volume to drop dramatically. This period was then followed by a second disrupted supply chain period where freight forwarders and carriers, looking for new routes for new volumes, turned to Teleroute to manage demand and the number of new users on Teleroute grew by 1,200.
Speaking about this trend, Fabrice Douteaud, COO of Teleroute, said: “We are very proud of the resilience shown by the transport & freight forwarding companies by continuing their important work during these very difficult times. We have experienced an exceptional demand for our freight exchange during this crisis, a proof of the value we bring to the market: facilitating the collaboration of transport professionals.”
France, the driving force behind the recovery of freight offers in Europe
After the month of April with volume below average, we are in the middle of the summer with a very notable recovery of the freight offers on Teleroute with France as the country of origin, which has doubled.
This leaves us with an activity in July that has far exceeded the monthly average number of published freight offers, mainly in the domestic market (90% of volumes) and in exports to Belgium, Germany and Spain in equal parts.
On the other hand, if we look at imports, the numbers are even better, in the last two months we find volumes well above the usual and that shows the recovery of the main countries that send merchandise to France: Italy, which leads the ranking with 37% of freight offers; Germany (29%), Belgium (23%) and Spain (7%).
Italy doubles its transport activity in July thanks to exports
Regarding the data obtained from the freight offers published on Teleroute originating in Italy, one of the countries most affected by the pandemic, we find a surprising recovery in July where the volume has doubled thanks to the reactivation of transactions with France, which account for 57% of Italian exports. Germany with 18% and Spain with 15% close the top 3.
In relation to inbound freight, the transalpine country doubled the number of import offers in July compared to previous months, placing activity above the average in 2019 and only slightly lower than the months with the highest activity on the freight exchange. A comeback led by the flow of goods with France, with 40% of the freight offers published, and Germany (15%) as the main countries offering freight to the Italian market.
Huge growth in the German domestic transport market
Focusing on Germany , another of the European economy's main drivers, we observed a strong rebound in activity in July with 25% above the monthly average in 2019, the domestic market's upward growth, which was already palpable in June, and accounting for 50% of the freight offers with Germany as origin and/or destination.
The other freight offers, are divided into 28% imports, mainly from Italy and France, and exports (remaining 22%) whose main destinations are France and the Netherlands.
Numbers that, in accordance with the offers registered in Teleroute, place the European transport market that Teleroute serves, already back to normal in practically the entire region and, on the current trajectory, will be performing ahead of 2019 for the remainder of the year.
Alpega Group
End-to-End Transportation software
Alpega Group is a leading global logistics software company offering modular solutions that cover all transportation and logistics complexity needs. By bringing together the best solutions and market expertise, the Alpega Group has created the transportation industry’s only scalable end-to-end software suite.
Alpega TMS empowers transport professionals to manage the logistics and supply chain processes, it transforms global and local supply chains into collaborative ecosystems, bringing together all parties involved. Alpega TMS’s unique scalability and best-in-breed standalone solutions ensure shippers benefit from a system that evolves alongside their needs, regardless of the complexity of their logistics processes. Our freight procurement solution, TenderEasy, provides a world-class solution for sourcing transportation providers across air, land and sea. In terms of freight exchanges, 123Cargo, Teleroute and Wtransnet are leading European marketplaces designed to match spot shipments and truck capacity.
These platforms and the data which flows through them, alongside our 30+ years’ experience in transportation lets us enable businesses to optimize their supply chain planning and execution while benefitting from lower costs and higher visibility. All of Alpega’s solutions combine to create added value for customers. Our community of 80,000 carriers and 200,000 members are electronically connected every day to successfully manage critical transport processes. Alpega is present in 80 countries worldwide and employs 500 people with 31 different nationalities.
More information can be found at www.alpegagroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom